RXi Pharmaceuticals (PHIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The market dynamics of Phio Pharmaceuticals (PHIO) securities demonstrate an EV/EBITDA ratio of 0.00. Phio Pharmaceuticals develops unique RNA delivery methods to combat oncology and dermatological pathologies. The stable operation of molecular complexes ensures an uninterrupted drug development cycle. Business efficiency is further enhanced by the implementation of robotic screening systems, which fully automate routine laboratory processes and accelerate the discovery of new medicines.
Comprehensive metric breakdowns and analytics for phiopharma.com (PHIO)
- stock price and consensus target price:
- market capitalization indicators:
- book value of equity indicators:
- debt burden and liquidity indicators:
- financial results and valuation multiples details:
PHIO - Company Net Income|Future Profit Phio Pharmaceuticals|PHIO - P/E Multiple|Projected Price to Earnings Phio Pharmaceuticals Corp.|PHIO - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple PHIO|PHIO - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Phio Pharmaceuticals|PHIO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth phiopharma.com|PHIO - Earnings growth in current year|Net earnings per share growth forecast for next year Phio Pharmaceuticals
Analysis of all company metrics:RXi Pharmaceuticals PHIO
For the biotechnology sector player Phio Pharmaceuticals (PHIO), the dynamics of the core EV/EBITDA multiple serve as an indicator of business value relative to its operating profit before depreciation and interest. This ratio compares the company's total enterprise value with its ability to generate cash flow, which is critical when assessing the capital-intensive development of the INTASYL platform and the efficiency of technology licensing.
Competitors of Phio Pharmaceuticals
tempus.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation QGEN|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RGEN|RNA: EV/EBITDA Multiple|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|WGS (Sema4) - EV/EBITDA Multiple|EV/EBITDA Multiple Ultragenyx Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|TXG - Enterprise Value to EBITDA Ratio|Intellia - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio wavelifesciences.com|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|EV/EBITDA Multiple Taysha Corp (TSHA)|uniQure N.V. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGTX (meiragtx.com)|REGENXBIO - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PacBio Corp|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple designtx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FDMT (4DMT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Total Company Value to Operating Income Before Depreciation Ratio Korro Bio Inc. (KRRO)|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SLN|PRQR: EV/EBITDA Multiple|Codexis - Business Value to Operating Income Before Depreciation|SGMO (Sangamo) - EV/EBITDA Multiple|Nautilus Biotechnology Inc (NAUT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|DTIL - Company Value to EBITDA|EV/EBITDA Multiple GBIO (Generation Bio)|BOLD: Enterprise Value to Operating Income Before Depreciation|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNN (Imunon, Inc.) - Enterprise Value to Operating Income Before Depreciation|MBIO: EV/EBITDA Multiple|TransCode Therapeutics, Inc. (RNAZ) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Applied DNA Sciences Inc - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BLUE|IPA (immunoprecise.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Syros Pharmaceuticals Inc.|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TRACON Pharmaceuticals, Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
